Document:

Assignment Agreement between Duska Scientific Co. and Dr. Amir Pelleg

 EXHIBIT 10.13 
  
 ASSIGNMENT AGREEMENT 
  
 This Assignment Agreement (this “Agreement”) is made as of December 18, 2003, by and between Dr. Amir Pelleg (“Pelleg”) of 24
Dartmouth Lane, Haverford, PA 19041-1020 and Duska Scientific Co., a Delaware corporation (“Duska”) having an office at Two Bala Plaza, Suite 300, Bala Cynwyd. PA 19004. 
  
 BACKGROUND 
  
 A. Pelleg is a scientist who is doing research in the field of P2 purinergic receptors. 
  
 B. Pelleg, together with Dr. Peter Barnes (“Barnes”) and Dr. Sergei Kharitonov (“Dr. Kharitonov”) are
listed as the inventors of an invention (the “Pelleg Invention”) relating to the pharmacologic modulation of P2 purinergic receptors located on nerve terminals known as the pulmonary rapidly adapting receptors for therapeutic, diagnostic
and prognostic purposes covered by a United States Provisional Patent Application No. 60/47,771 dated June 16, 2003, titled “Methods of Modulating Cough in Humans and Animals” (the “Patent Application”). 
  
 C. Duska and Pelleg believe that the Pelleg Invention can potentially be
commercialized as new products such as the one they have named AspirexTM and which is more fully described in Exhibit A hereto. 
  
 D. Duska is an early-stage company that desires to obtain an assignment from Pelleg of all of his rights, title and interest in and to the Pelleg Invention. 
  
 E. Pelleg is desirous of assigning of all of his rights, title and interest
in and to the Pelleg Invention to Duska. 
  
 NOW, THEREFORE, in
consideration of the promises and covenants contained in this Agreement and intending to be legally bound, the parties agree as follows: 
  
 ARTICLE 1 
  
 ASSIGNMENT AND LICENSE GRANT 
  
 1.1 Assignment. Pelleg hereby assigns, transfers and conveys to Duska, and its successors and assigns, all of his right, title and interest in and to the Pelleg Invention and any related intellectual property
owned by him, including without limitation, the Patent Application and any other related patents and patent applications or subsequent improvements thereto, whether United States or foreign, which at any time may be granted, including any and all
renewals, reissues, divisionals and prolongations thereof or based thereon, including the right to sue for and recover all damages for past infringements (collectively, the “Pelleg Invention Assigned Property”). The Pelleg Invention
Assigned Property is assigned by Pelleg to Duska (the “Assignment”) free and clear of all liens, claims and encumbrances. 
  

 ARTICLE 2 
  

FEES AND ROYALTIES 
  
 2.1 Assignment Fee. As payment in full by Duska to Pelleg for the Assignment, Duska shall issue to Pelleg an option (the “Option”) under
Duska’s 2000 Stock Option Plan (or outside of the Plan if Duska is unable to increase the size of the Plan to permit issuance of the Option under the Plan) to purchase 75,000 shares of Duska common stock at an exercise price of $3.125 per
share. The Option shall be exercisable at any time within seven years from the date of this Agreement as to the vested portion of the Option. The Option shall vest upon the execution of this Agreement as to 25,000 shares, with the remaining 50,000
shares to vest upon the issuance of a U.S. Patent with claims sufficiently broad to cover AspirexTM (as described in Exhibit A) or any other diagnostic or therapeutic product related to cough having commercial potential at least comparable to that of AspirexTM (a “Qualifying Patent”). 
  
 ARTICLE 3 
  
 DILIGENCE AND ABANDONMENT 
  
 3.1 Diligence and Patent Filings. Duska shall use its commercially reasonable efforts to secure the issuance of a Qualifying Patent. However, all
decisions concerning the pursuit of patent coverage for the Pelleg Invention (including any decision to abandon such pursuit) shall be made solely by Duska’s Board of Directors. Duska will retain control over, and will diligently prosecute and
maintain at its sole expense the patents and patent applications included in the Pelleg Invention Assigned Property. Duska will consult with Pelleg prior to the filing of any patent application in any jurisdiction, but decisions as to the filing of
patent applications or maintenance of patents in any jurisdiction will be made by Duska at its sole discretion. Duska will furnish to Pelleg in a timely fashion copies of all documents relevant to any such prosecution and maintenance. Duska will
have the right at its sole discretion to transfer the prosecution and maintenance of patents and patent applications to any experienced patent attorney of Duska’s choosing. 
  
 3.2 Abandonment. If Duska decides to abandon the pursuit of patent coverage of Pelleg Invention, Duska, its successor
or its assigns will notify Pelleg promptly of its decision and will reassign to Pelleg at no cost to Pelleg all of its rights, title and interest in and to the Pelleg Invention, except that Pelleg will reimburse Duska for its out-of-pocket costs
incurred in pursuing such patent coverage. Duska shall have no other obligation or liability to Pelleg in connection with any abandonment of the pursuit of patent coverage for the Pelleg Invention. 
  
 ARTICLE 4 
  
 REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION 
  
 4.1 Representations and Warranties. Pelleg represents and warrants that the Assignment will not violate any agreement
to which he is a party, that Drs. Barnes and Kharitonov and he are the sole inventors of the Pelleg Invention and the sole owners of the Pelleg Invention Assigned Property and that Drs. Barnes and Kharitonov have assigned to Duska all of their
right, title and interest in and to the Pelleg Invention Assigned Property. To the best 

  

 2 

 
knowledge of Pelleg, none of the Pelleg Invention Assigned Property infringes any patent, trade secret or other property or proprietary rights of any third
party. Pelleg hereby acknowledges that (i) Duska and its officers and directors have made no representations to him concerning the timing or probabilities of obtaining any Qualifying Patent or any governmental marketing approvals for AspirexTM or the potential markets for this product; (ii) there
is no assurance that AspirexTM will be successfully
developed by Duska or governmental marketing approvals will be obtained or that commercially viable markets for AspirexTM will exist; and (iii) obtaining a Qualifying Patent and the development of AspirexTM will require expenditures substantially in excess of Duska’s current financial
resources and that there is no assurance that Duska will be able to generate sufficient capital to fund these activities. Pelleg also represents that he has been advised by his own counsel (which is independent of Troy & Gould or any other
counsel representing Duska) in connection with this Agreement. 
  
 4.2 Indemnification. Pelleg will indemnify, defend and hold Duska and Duska’s officers, directors, shareholders, agents and employees harmless from and against any and all liability, loss, damage, action, claim or expense
incurred by any of the foregoing parties excluding any consequential damages or lost opportunity profits or costs) resulting from any breach of Pelleg’s representations, warranties or covenants under this Agreement, including without limitation
any claims asserted by Drexel University College of Medicine relating in any manner to the Pelleg Invention Assigned Property. Duska will indemnify, defend and hold harmless to the extent of Duska’s assets (including any insurance policies)
Pelleg, from and against any and all liability, loss, damage, action, claim or expense suffered or incurred by him (including reasonable attorneys’ fees and expenses but excluding any consequential damages or lost opportunity profits or costs)
that results from any breach by Duska of its covenants under this Agreement. 
  
 ARTICLE 5 
  
 ADDITIONAL
PROVISIONS 
  
 5.1 No Agency. Nothing in this Agreement
shall be deemed to establish a relationship of principal and agent between Pelleg and Duska or its sublicensees, nor any of their agents or employees for any purpose whatsoever, nor shall this Agreement be construed as creating any other form of
legal association or arrangement which would impose liability upon one party for the act or failure to act of the other party. 
  
 5.2 Assignment. Duska may grant licenses to third parties to any of its rights in the Pelleg Invention Assigned Property. Duska and any licensees
are permitted to assign this Agreement, either directly or by merger or other operation of law. 
  
 5.3 No Waiver. No waiver of any breach or condition of this Agreement shall be deemed to be a waiver of any other subsequent breach or condition,
whether of like or different nature. 
  
 5.4 Notices. All
notices, requests, consents and other communications hereunder shall be in writing and shall be delivered in person or sent overnight delivery by Federal Express or by certified or registered mail, return receipt requested, or telexed in the case of
non-U.S. residents, and shall be deemed to have been given when hand delivered, one (1) day after mailing 

  

 3 

 
when mailed by overnight courier (e.g. Federal Express or Express Mail) or five (5) days after mailing by registered or certified mail, as follows (provided
that notice of change of address shall be deemed given only when received): 
  
 If to Pelleg: 
  
 Dr. Amir Pelleg

 24 Dartmouth Lane 
 Haverford,
PA 19041-1020 
  
 If to Duska: 
  
 Duska Scientific Co. 
 Two Bala Plaza 
 Suite 300 
 Bala Cynwyd, Pennsylvania 19004 
 Attention:
Chief Executive Officer 
  
 With a required copy to: 

 
 Dale Short, Esq. 
 Troy & Gould 
 Suite 1600 
 1801 Century Park East 
 Los Angeles, CA 90067

  
 or to such other names or addresses as Duska or Pelleg, as
the case may be, shall designate by notice to each other person entitled to receive notices in the manner specified in this Section 5.4. 
  
 5.5 Governing Law and Jurisdiction. This Agreement shall be construed and governed in accordance with the laws of the Commonwealth of Pennsylvania,
without giving effect to conflict of law provisions of any jurisdiction. 
  
 5.6 Binding Nature of Agreement. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, personal representatives, successors and assigns. 
  
 5.7 Integration and Amendment. This Agreement embodies the entire
agreement and understanding between the parties hereto and thereto and supersedes all prior agreements and understandings relating to the subject matter hereof or thereof. This Agreement may not be changed, modified, extended or terminated except by
written amendment executed by an authorized representative of each party. 
  
 5.8 Severability. If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, then such illegality, invalidity or unenforceability shall attach only to such provision and shall not
in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be carried out as if any such illegal, invalid or unenforceable provision were not contained herein. 
  

 4 

 5.9 Force Majeure. Any delay or failure to perform any part of this Agreement arising from causes
beyond the reasonable control of the party concerned shall not be deemed to be a default under this Agreement. Causes beyond the reasonable control of a party shall include, without limitation,, Labor disturbances or labor disputes of any kind,
civil disorders or commotions, accidents, failure of any governmental approval required for full performance, energy or other conservation measures imposed by law or regulation, explosions, failure of utilities, mechanical breakdowns, material
shortages, or other such occurrences. 
  
 5.10 Interpretation
of Agreement. In interpreting this Agreement, there shall be no presumption against the party principally responsible for the drafting of this Agreement. 
  
 IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this Agreement to be executed by their duly authorized representatives.

  

	
	
	 /s/ Amir Pelleg

	 DR. AMIR PELLEG

  

			
		
	 By:
	 	 /s/ Manfred Mosk

	 Name:
	 	 Manfred Mosk

	 Title:
	 	 Chief Executive Officer

	 Date:
	 	 

  

 5Assignment among Duska Scientific Co., Dr. Amir Pelleg & Dr. Edward S. Schulman

 EXHIBIT 10.14 
  
 ASSIGNMENT 
  
 WHEREAS, Amir Pelleg of 24 Dartmouth Lane, Haverford, Pennsylvania 19041-1020 and Edward S. Schulman of 911 Bonaparte Court, Philadelphia, Pennsylvania
19107, hereinafter generally referred to as “ASSIGNORS”, are the owners, by assignment, of the inventions disclosed and claimed in the following U.S. and patent arid patent application: 
  

					
	 Patent No/
 Patent Application
No.

	  	 Issue Date/
 Filing Date

	  	 Title

	 Patent Application No.
 09/381,692
	  	 December 2, 1999
	  	 Modulation of Human Mast
 Cell Activation

	U.S. Patent No. 5,874,420	  	 February 23, 1999
	  	 A Process for Regulating
 Vagal Tone

  
 WHEREAS, Duska
Scientific Co., a corporation organized and existing under the laws of the State of Delaware, having a place of business at 24 Dartmouth Lane, Haverford, Pennsylvania 19041-1020, hereinafter generally referred to as “ASSIGNEE,” is desirous
of acquiring said inventions and said Letters Patent, including any choses in action; 
  
 NOW, THEREFORE, in consideration of the sum of One Dollar and other good and valuable executed consideration, the full receipt and sufficiency of all of which are hereby acknowledged, and intending to be legally bound
hereby, WE, the undersigned ASSIGNORS, hereby agree to sell, assign, transfer and convey and by these presents do sell, assign, transfer and convey unto the above-named ASSIGNEE, the whole and entire right, title and interest 
  
 in and to said inventions as described above, for the
territory of the United States and its possessions and territories and all foreign countries, and 
  
 in and to the above Letters Patent and application for Letters Patent, and any and all United States Letters Patent which may be granted
on said application and all United States and foreign Letters Patent which may be granted on said inventions including divisions, reissues and continuations, including the right to sue for and recover all damages for past infringements; 

 
 said inventions, application and Letters Patent to he held and enjoyed by the above-named
ASSIGNEE, for ASSIGNEE’S own use and behoof, and for ASSIGNEE’S legal representatives and assigns to the full end of the term or terms for which said Letters Patent may be granted, as fully and entirely as the same would have been held by
the undersigned ASSIGNORS had this assignment and sale not been made; and for the aforesaid consideration ASSIGNORS hereby covenants, agrees and undertakes to execute, whenever requested by the above-named ASSIGNEE, all patent applications,
assignments, lawful oaths and any other papers which ASSIGNEE may deem necessary or desirable for securing to ASSIGNEE or for maintaining for ASSIGNEE all the Letters Patent hereby assigned or agreed to be assigned; all without further compensation
to the undersigned ASSIGNORS and the choses in action therefor, all without further compensation to ASSIGNEE. 
  

			
		
	 By:
	 	 /s/ A. Pelleg

	 	 	Amir Pelleg

  
 NOTARIAL
CERTIFICATION 
  

					
	 Commonwealth of Pennsylvania
	  	 	  	 
	 	  	 ss
	  	 
	 County of Philadelphia
	  	 : Philadelphia
	  	 

  
 BEFORE ME, the
undersigned Notary Public, on this 14th day of December, 2001 personally appeared Amir Pelleg, personally known to me (or proven to me on the basis of satisfactory evidence) to be the person who executed the foregoing instrument, and
acknowledged to me that the instrument was the free deed and act of said corporation for the purposes therein set forth and intending that this instrument be recorded 
  

					
	[seal]	  	/s/ Sheila M. Gillespie	  	NOTARIAL SEAL
	 	  	NOTARY PUBLIC	  	 Sheila M. Gillespie, Notary Public
 City of Philadelphia, Phila. County
 My commission expires Dec. 25, 2003

  

			
		
	 By:
	 	 /s/ Edward S. Schulman

	 	 	Edward S. Schulman

  
 NOTARIAL
CERTIFICATION 
  

					
	 Commonwealth of Pennsylvania
	  	 	  	 
	 	  	 ss
	  	 
	 County of Philadelphia
	  	 :
	  	 

  
 BEFORE ME, the
undersigned Notary Public, on this 14th day of December, 2001 personally appeared Edward S. Schulman, personally known to me (or proven to me on the basis of satisfactory evidence) to be the person who executed the foregoing
instrument, and acknowledged to me that the instrument was the free deed and act of said corporation for the purposes therein set forth and intending that this instrument be recorded 
  

					
	[seal]	  	/s/ Sheila M. Gillespie	  	NOTARIAL SEAL
	 	  	NOTARY PUBLIC	  	 Sheila M. Gillespie, Notary Public
 City of Philadelphia, Phila. County
 My commission expires Dec. 25, 2003

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00074-of-00352.parquet"}]]